Discussing the Investigation of Polatuzumab Combination Therapy in DLBCL
October 24th 2023Elizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.